about
Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infectionA Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected PatientsA Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance and Tropism Testing Using 454 Ultra Deep PyrosequencingChallenges and opportunities in estimating viral genetic diversity from next-generation sequencing dataProfound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infectionMolecular characterisation of Lac s 1, the major allergen from lettuce (Lactuca sativa).In Vivo and in Vitro Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4+ T Cells.A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replicationFull-length haplotype reconstruction to infer the structure of heterogeneous virus populations.Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cellsBlinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.A framework for inferring fitness landscapes of patient-derived viruses using quasispecies theory.Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombinationLow-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013.HIV-1 RNAs are Not Part of the Argonaute 2 Associated RNA Interference Pathway in Macrophages.Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.Monocyte-derived macrophages exhibit distinct and more restricted HIV-1 integration site repertoire than CD4(+) T cells.Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairsSynthetic pre-microRNAs reveal dual-strand activity of miR-34a on TNF-α.Unravelling HIV-1 Latency, One Cell at a Time.Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships.MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing.Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection.A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replication.The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro.Reply to correspondence 'Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic" process' by Gonzalez et al., Retrovirology 2017.A Comprehensive Analysis of Primer IDs to Study Heterogeneous HIV-1 Populations.Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected Eritrean immigrant.Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing.Evaluation of CD8+ T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus.Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.
P50
Q28478934-8D4C5AFB-F8F3-4C5E-97C1-51343FCD89BBQ28546535-243B621F-5AC0-43DB-9007-36A78316CAFAQ28552356-022FA4F7-D4F4-4657-B107-BA7EFCAEB618Q28727944-314E4E3F-4082-45E4-AD21-479657E29B20Q28748901-0520F47F-971E-4566-937A-2473D2B62D95Q30360313-A826958A-D042-456F-AFCD-21FF64226277Q30398955-F481D00F-5E76-4594-A277-6D10EC38D1BDQ33790492-DC2793A8-8A3F-4446-AA8E-8DA7693F491EQ34044256-9F10D3AB-C473-44AD-82EE-0FB760E49E32Q34212555-0A84C925-E2B7-4E5E-B7EC-16A8F8007FCCQ34719734-FAF34214-4C96-4DFD-A23A-1D4C5562D880Q34864202-A75A21FA-9111-4B7A-868B-4A40A256FAA5Q34994579-B7671AE0-FB3A-4B4A-B6F2-5FD7FDD49A52Q35056873-3EF79A3B-1A84-4E38-8634-DC055CD56BD2Q35628314-676F31B3-9840-4CA7-9279-35498CCBD2C9Q35726813-A9D00069-DA9E-402F-9B8A-5749259421CCQ36298503-7427A33C-8A35-4004-9D3A-16A0697DD825Q36607276-88C3B375-56E4-49C3-8BD3-F1B06E115F6AQ36747913-83CA19FC-1840-40C2-8734-F3A67FCE198BQ36790007-D18437C2-1458-429D-97FE-C9FB5EB36B5EQ37233074-2F1A98A7-E291-4C8E-8CD1-EDB2ED5F4455Q37400278-86206023-6366-4590-920D-2690307180BAQ38664072-9B60C05B-0E35-4454-9D67-8760F68B5985Q38853942-2D10C57A-4C14-4159-9604-53F4224DFC10Q39170603-C633F1D0-1BCD-46D9-9296-B1D55528125BQ39398170-7B2DE4EB-64A6-4ED2-B0D7-7032F6F59F9EQ39699276-22CB87E0-9CBD-4C4C-AA09-069B530876D3Q39725663-DAA9ED5F-361C-4373-9E5A-907F6E9DC27CQ40320261-5BFEC606-FBC2-4CB9-84AA-4A2AE02572CAQ40854420-39E69E00-C8BE-4594-AA1B-60BD9D56834CQ42205529-18779706-E758-4F5E-896E-C9A7494C2E01Q42212364-B68BDC8E-3029-42F8-A62A-BE8DC72F3D11Q42219452-F78FBDEC-71E5-47E4-9232-B4A7A27696FCQ42255433-A7EAA481-CAD6-48A6-8174-C4E5FEA5ABA7Q42572272-A1EC0E88-9288-4F36-AACF-1D074D9B7398Q43011767-AC0E7E5E-9089-4EDA-932E-FAA07A8C2C25Q43145005-85E42A7B-F9C6-4EEC-AC7D-2D3F3D982126Q44197028-DBF31CF8-76F4-41F0-AA23-6DDB7D3FA4AAQ45422359-7F09CCFB-1A1F-4827-BA71-0E638A5B4150Q45709309-8FCA4FE2-75B2-4F4F-9159-3B417FB2964A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Karin J Metzner
@ast
Karin J Metzner
@en
Karin J Metzner
@es
Karin J Metzner
@nl
Karin J Metzner
@sl
type
label
Karin J Metzner
@ast
Karin J Metzner
@en
Karin J Metzner
@es
Karin J Metzner
@nl
Karin J Metzner
@sl
prefLabel
Karin J Metzner
@ast
Karin J Metzner
@en
Karin J Metzner
@es
Karin J Metzner
@nl
Karin J Metzner
@sl
P1053
G-5319-2011
P106
P21
P31
P3829
P496
0000-0003-4862-1503